Gateway 2011: Ropack Inc. - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Gateway 2011: Ropack Inc.

Your online Gateway to Ropack Inc. in 2011

10801 Mirabeau Street,
Montreal QC H1J 1T7
513 846-0921

About Ropack Inc.


Watch our video


Ropack offers turnkey primary and secondary pharmaceutical packaging services of solid oral dosages, tablets, powder, and encapsulation into blisters, pouches, bottles, stick packaging and carded blisters. Ropack recently added syringe assembly and vial labeling capabilities. Facilities are cGMP compliant, FDA certified and have 25 Class 100000 production rooms. Ropack is competitive, flexible and agile, supporting clinical trials, short-run start-ups, commercial production for more than 100 U.S., Canadian and European pharmaceutical customers.


Ropack has more than ten years of experience packaging temperature- and humidity-sensitive materials.  Our proven record of accomplishment in new product launches will support and accelerate your go-to-market timeline.

See what's new from Ropack's turnkey primary and secondary pharmaceutical and nutraceutical packaging services, including the latest advancements in blisters at Interphex 2011.Now Ropack offers stick packaging – slim, tube-shaped uni-dose packaging of solid oral dosage in a low relative humidity, controlled residual oxygen and temperature-controlled environment.  Stick packaging is popular in Japan and Europe for its accuracy and convenience, and now Ropack is advancing stick packaging technology in North America. 

Ropack now offers manufacturing and packaging environments to meet even the most exacting specifications.  A new 15,000-square-foot dedicated production suite is temperature-controlled with low RH (20%) and controlled residual oxygen (< 2%). Like all Ropack facilities, it is cGMP compliant, FDA certified and Health Canada approved.


New Products
and Releases
New Whitepapers

Ropack Enhances Services with Controlled Production Environment

Stick packaging



For more information:

To schedule a meeting, call or text Paul Dupont, Director of Business Development, at 513 846-0921, or email him:




blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here